This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India

This study has been completed.
Information provided by (Responsible Party):
Pro Top & Mediking Company Limited Identifier:
First received: May 23, 2007
Last updated: February 24, 2014
Last verified: February 2014
  1. . Study Objective: The objective of this study is to determine the safety and effectiveness of the OculusGenTM Biodegradable Collagen Matrix Implant in phacotrabeculectomy surgery. The primary endpoint is to prove the effectiveness via the reduction of Intraocular Pressure, and the secondary endpoint is to prove the safety via the incidence of complications and adverse events.
  2. . Study Design: The study is designed as a historical controlled study. Patient who meet the inclusion/exclusion criteria and sign the informed consent form will be included for this study. The allocation of subjects is non-randomized, and there is a single group for assignment.
  3. . Follow-Up: This investigation is including 7 post-operative visits and follow-up within 6 months from the date of surgery. Patients should be seen at postoperative days 1, 7, 14, 30, 60, 90 and 180. The visit window of ± 7 days is allowed for the 30, 60, 90 and 180 day visits. The further follow-up of subject after trial is continually tracked by the investigator.

Condition Intervention Phase
Glaucoma Cataract Device: OculusGen Biodegradable Collagen Matrix Implant Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Study of the Safety and Effectiveness of the OculusGenTM Collagen Matrix Implant as an Aid in Phacotrabeculectomy Surgery

Resource links provided by NLM:

Further study details as provided by Pro Top & Mediking Company Limited:

Primary Outcome Measures:
  • Preoperative and Postoperative Intraocular Pressure [ Time Frame: baseline and 90 days ]
    The preoperative and postoperative intraocular pressure is measured as mmHg at baseline and 90 days.

Secondary Outcome Measures:
  • Number of Participants With Any Complications or Adverse Events. [ Time Frame: 180 day ]
    Observation of the incidence of complications, including transient shallow anterior chamber, hyphema, choroidal detachment, hypotony or endophthalmitis.

Enrollment: 10
Study Start Date: May 2007
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OculusGen Collagen Matrix
OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
Device: OculusGen Biodegradable Collagen Matrix Implant
OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Subject inclusion criteria:

  1. Age 18 years or over.
  2. At least one eye diagnosed with glaucoma and receiving maximally tolerated medical therapy.
  3. Visually significant cataract with visual acuity of less than or equal to 6/12.
  4. Subject able and willing to cooperate with investigation plan.
  5. Subject willing to sign informed consent form.

Subject exclusion criteria:

  1. Known allergic reaction to collagen.
  2. Subject is on Warfarin and discontinuation is not recommended.
  3. Subject with normal tension glaucoma or aphakic glaucoma.
  4. Subject with corneal disease.
  5. Participation in an investigational study during the 30 days proceeding phacotrabeculectomy.
  6. Ocular infection within 14 days prior to phacotrabeculectomy.
  7. Pregnant or breast-feeding women.
  8. Monocular subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00477685

Grewal Eye Institute
Chandigarh, India, 500 034
Sponsors and Collaborators
Pro Top & Mediking Company Limited
Principal Investigator: SPS Grewal, MD Grewal Eye Institute
  More Information

Responsible Party: Pro Top & Mediking Company Limited Identifier: NCT00477685     History of Changes
Other Study ID Numbers: Mediking 0704
OculusGen-2007-04-20 ( Other Identifier: Aeon Astron Europe B.V. )
Study First Received: May 23, 2007
Results First Received: October 24, 2011
Last Updated: February 24, 2014

Keywords provided by Pro Top & Mediking Company Limited:
Collagen matrix
anti scarring
tissue engineering
Aeon Astron

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Lens Diseases processed this record on July 21, 2017